A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

  • End date
    Jun 29, 2023
  • participants needed
  • sponsor
    Incyte Corporation
Updated on 31 March 2021


The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination of parsaclisib and ruxolitinib in subjects with myelofibrosis.

Condition Myelosclerosis with myeloid metaplasia, MPN (Myeloproliferative Neoplasms), MPN, Myelofibrosis
Treatment Ruxolitinib, INCB050465, Parsaclisib
Clinical Study IdentifierNCT02718300
SponsorIncyte Corporation
Last Modified on31 March 2021

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note